Journals / Glokom Katarakt / 2017 / Cilt: 12 - Sayı: 2

GÜNCEL KONU / QUEST EDITORIALS

Glokomun Tıbbi Tedavisinde Yenilikler

Pages
81–87
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Researchers have made great steps in both identifying potential treatment targets and creating novel medical delivery systems that may benefi t patients affected by glaucoma in future.In this review, new FDA-approved drugs and ongoing medications will be tried to oversight for glaucoma medical treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glaucoma is a devastating and insidious disease that causes irreversible blindness in millions of people worldwide.
📊
Key Findings & Data:The large number of phase 3 studies are carried out to broaden the medical treatment options for glaucoma management in the near future.
💡
Conclusion & Impact:Researchers have made great steps in both identifying potential treatment targets and creating novel medical delivery systems that may benefi t patients affected by glaucoma in future.In this review, new FDA-approved drugs and ongoing medications will be tried to oversight for glaucoma medical treatment.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Glaucoma is a devastating and insidious disease that causes irreversible blindness in millions of people worldwide. Intraocular pressure (IOP) is still the only controllable major risk factor. Antiglaucomatous medical treatment is often used as a fi rst line therapy . The large number of phase 3 studies are carried out to broaden the medical treatment options for glaucoma management in the near future. Researchers have made great steps in both identifying potential treatment targets and creating novel medical delivery systems that may benefi t patients affected by glaucoma in future.In this review, new FDA-approved drugs and ongoing medications will be tried to oversight for glaucoma medical treatment.

Özet

Glokom, tüm dünyada milyonlarca insanda geri dönüşümsüz körlük nedeni olan yıkıcı ve sinsi bir hastalıktır. Gö z iç i basınç (Gİ B), halen kontrol edilebilir tek majö r risk faktö rü dür. GİB düşürülmesinde birinci basamak tedavide sıklıkla tıbbi tedavi kullanılmaktadır. Halen pek çok Faz 3 çalışma, yakın gelecekte glokom yönetimine yönelik tıbbi tedavi seçeneklerinin genişletilmesi için yürütülmektedir. Araştırmacılar hem potansiyel tedavi hedefl erini belirlemekte hem de gelecekte glokomdan etkilenen hastalara fayda sağlayabilecek yeni ilaç verme sistemleri yaratmada büyük adımlar atmışlardır. Bu derlemede glokomun tıbbi tedavisinde yeni FDA onayı almış olan veya üzerinde çalışmalar devam eden ilaçlar gözden geçirilmeye çalışılacaktır.

🔖

Cite This Article

MALKOÇ, E. Ş. (2017). GÜNCEL KONU / QUEST EDITORIALS. Glokom Katarakt, Cilt: 12 - Sayı: 2, 81–87. https://ajindex.com/articles/226814

References (15)

  1. Tham YC, Li X, Wong TY, et al: Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121:2081-90
  2. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965-72
  3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-13
  4. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-97
  5. Schehlein EM, Novack GD, Robin AL. New classes of glaucoma medications. Curr Opin Ophthalmol. 2016 Nov 8. [Epub ahead of print] 6. Wentz SM, Kim NJ, Wang J, et al. Novel therapies for open-angle glaucoma. F1000Prime Rep. 2014 Nov 4;6:102. doi: 10.12703/P6- 102
  6. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science.1999;285:895-8
  7. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446-56
  8. Shen X, Koga T, Park BC, et al. Rho GTPase and cAMP/protein kinase A signaling mediates myocilin-induced alterations in cultured human trabecular meshwork cells. J Biol Chem. 2008;283:603-12
  9. Pattabiraman PP, Maddala R, Rao PV. Regulation of plasticity and fi brogenic activity of trabecular meshwork cells by Rho GTPase signaling. J Cell Physiol.2014;229:927-42
  10. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245-8
  11. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-14
  12. Wang SK, Chang RT. An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol. 2014;8: 883-90
  13. Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288-95
  14. Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731-6
  15. Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-l